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Background: Recent studies have shown dysregulation in TJ structure of several cancers including breast. Claudin-5
is a protein member of the TJ structure expressed in both endothelial and epithelial cells. This study examined the
level of expression and distribution of Claudin-5 in human breast cancer tissues and the effect of knockdown and
forced expression of Claudin-5 in the MDA-MB-231 breast cancer cell line.
Methods: Immunohistochemistry and quantitative-PCR were used to analyse patient tissue samples. The Claudin-5
gene was cloned and overexpressed or knocked down using ribozyme technology in human breast cancer cells.
Changes in function were assessed using in vitro assays for invasion, growth, adhesion, wounding, motility,
transepithelial resistance and electric cell-substrate impedance sensing. Changes in cell behaviour were achieved
through the use of Hepatocyte Growth factor (HGF) which we have shown to affect TJ function and expression of
TJ proteins. In addition, an in vivo model was used for tumour growth assays. Results data was analyzed using a
Students two sample t-test and by Two-way Anova test when the data was found to be normalized and have
equal variances. In all cases 95% confidence intervals were used.
Results: Patients whose tumours expressed high levels of Claudin-5 had shorter survival than those with low levels
(p = 0.004). Investigating in vitro the effect of altering levels of expression of Claudin-5 in MDA-MB-231cells revealed that
the insertion of Claudin-5 gene resulted in significantly more motile cells (p< 0.005). Low levels of Claudin-5 resulted in
a decrease in adhesion to matrix (p< 0.001). Furthermore, a possible link between Claudin-5 and N-WASP, and Claudin-
5 and ROCK was demonstrated when interactions between these proteins were seen in the cells. Moreover, followed by
treatment of N-WASP inhibitor (Wiskostatin) and ROCK inhibitor (Y-27632) cell motility was assessed in response to the
inhibitors. Results showed that the knockdown of Claudin-5 in MDA-MB-231 masked their response after treatment with
N-WASP inhibitor; however treatment with ROCK inhibitor did not reveal any differences in motility in this cell line.
Conclusions: This study portrays a very new and interesting role for Claudin-5 in cell motility involving the N-WASP
signalling cascade indicating a possible role for Claudin-5 in the metastasis of human breast cancer.
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Metastasis is the presence of disease at distant sites due
to the spread of cancer cells which results is overwhelm-
ing mortality in patients with cancer accounting for al-
most 90% of all cancer related deaths [1]. The process of
cancer metastasis consists of linked sequential steps, so
called metastatic cascade, including detachment, inva-
sion, intravasation, circulation, adhesion, extravasation,
and growth in distant organs. Extensive interactions be-
tween tumours cells and surrounding tissues during
their dissemination complicate the analysis of signalling
events during the cascade. Due to its complex nature,
the understanding of the cellular and molecular factors
is limited [2]. Most cancers, including breast cancer, ori-
ginate from epithelial tissues and are characterized by
abnormal and uncontrolled growth as well as presenting
disorders in cell communication. Additionally underlying
changes include changes in cell-cell and cell-substrate
adhesion, a fundamental step allowing cancer cells to
spread and ultimately metastasise. In order to activate
the metastatic cascade, cancer cells must acquire a mo-
tile phenotype. Cell motility is orchestrated by a variety
of complicated signal pathways, most of which are just
starting to be unravelled. Motility occurs in response to
chemokines or growth factor signals. In response to
these stimuli, changes in the cytoskeleton, in the cell-cell
adhesion structures and in the extracellular matrix
(ECM) take place resulting in a motile cell capable of
gaining access to the systematic circulation and ultim-
ately metastasis [3].
Studies have shown that several Tight Junction (TJ)
components are directly or indirectly involved in breast
cancer progression and metastasis [4-8]. TJ are highly
regulated areas of adhesion between cells. They are the
most apical component of the lateral plasma membrane
and create a regulated paracellular barrier to the move-
ment of ions, solutes and immune cells between the cells
and signalling pathways that communicate cell position,
limit growth and apoptosis [9]. Claudins are members of
the network of proteins that constitute the TJ structure.
The main role of Claudins is in the regulation of para-
cellular selectively to small ions through the pores that
themselves are capable of forming [10]. However, new
roles for Claudins have challenged the idea that Claudins
function only as sealing proteins. Claudins have now
been shown to be involved in cellular growth and in epi-
thelial-mesenchymal transition (EMT) [11]. These results
suggest that Claudins play multiple roles beyond acting as
a “doorman” in the paracellular barrier opening a new
field of research. Most epithelial and endothelial cells ex-
press a mixture of different Claudin proteins and more
than two different Claudin members are co-expressed in a
single cell [12]. Claudin proteins are co-polymerised to
form TJ strands as heteropolymers, and in a homophilicmanner, between two molecules of the same Claudin
member, or heterophilic manner between two different
Claudin members [13]. The Claudin family is composed of
more than 20 members in mammals of around 22 to
27 kDa. Claudins were first identified by Furuse et al.,
using the same isolated fraction from chicken liver from
which Occludin was first identify by Tsukita’s group in
1989 [14]. They showed for the first time that a group of
proteins existed with similar sequence to each other and
with four transmembrane domains where the N- and C-
terminal domains are orientated towards the cytoplasm,
but with no similarity to Occludin. At their C-termini,
Claudins generally have a valine residue and all members
have a PDZ domain that allows them to interact with other
proteins in the TJ such as ZO-1, -2, and -3, MUPP, and
PATJ. The interaction with cytoplasmic plaque proteins
such as ZO-1 links Claudins to the actin cytoskeleton [15].
Claudin-5 was firstly described by Morita et al. [16]. It
was initially identified as a deleted protein in patients
who suffer from the velo-cardio-facial syndrome heredi-
tary disease and was termed TMVCF (transmembrane
protein deleted in velo-cardio-facial syndrome) and the
gene was mapped to chromosome 22q11. It has been
described as being expressed in the brain, lung and
endothelial cells of the blood vessels concluding that
Claudin-5 was an endothelial-specific component of the
TJ strand [16]. However, several studies have reported
Claudin-5 to be expressed in certain epithelial TJs, such
as, the stomach, rat liver and pancreas [17] as well as in
cell lines like HT-29/B6, an epithelial cell derived from
human colon [18]. Studies focusing on blood-brain bar-
rier (BBB) have proposed a “sealing” role for Claudin-5
[19,20]. Claudin-5 knock down mice were generated
have shown a normal development and morphology of
blood vessels in the brain, however, in terms of the bar-
rier function, these endothelial cells showed an unex-
pected feature: a size-selective loosening of the BBB, in
other words, only small molecules (<800 Da) were
allowed to pass across the TJ but no larger molecules
were affected. Moreover, Claudin-5 deficient mice died
within 10 hours of birth [20]. Therefore, it appears that
loss of Claudin-5 from the TJ complexes in the brain
can compromise barrier function making it “leakier”
while keeping their structural integrity.
Previous work from Martin et al. studied the expres-
sion of different TJ molecules in breast cancer leading to
this current study examining the effect of Claudin-5
over-expression and knockdown in human breast cancer
cells and the expression and distribution of Claudin-5 in
human breast cancer tissues [21,22]. Following confirm-
ation of the levels of expression, the cells were used in a
number of in vitro and in vivo experimental assays in
order to clarify a possible role of Claudin-5 in breast can-
cer progression. Additionally, Claudin-5 was examined in
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know that HGF modulates the function of TJ and the ex-
pression of several TJ molecules including Claudin-5 [21],
and a possible role of Claudin-5 on control of cell motility
involving the N-WASP and ROCK signalling pathways
was revealed.
Methods
Reagents and antibodies
Mouse anti-Claudin-5 (H00007122-A01) was obtained
from Abnova (Abnova GmbH, Heidelberg, Germany),
rabbit anti-Claudin-5 (sc-28670) from Santa-Cruz Bio-
technologies Inc. (Santa Cruz, USA), anti-actin (sc-
8432) from Santa-Cruz Biotechnologies Inc. (Santa
Cruz, USA), goat anti-N-WASP (sc-10122) from
Santa-Cruz Biotechnologies Inc. (Santa Cruz, USA),
mouse anti-ROCK 1 (sc-17794) from Santa-Cruz Bio-
technologies Inc. (Santa Cruz, USA), secondary anti-
body anti-mouse peroxidase conjungated (A-9044)
from Sigma (Sigma-Aldrich, Dorset, UK), secondary
antibody anti-goat peroxidase conjungated (A-5420)
from Sigma (Sigma-Aldrich, Dorset, UK) secondary
antibody anti-rabbit peroxidase conjungated (A-6154)
from Sigma (Sigma-Aldrich, Dorset, UK). N-WASP
inhibitor Wiskostatin (681660-1 MG) from Calbio-
chem (Gibbstown, USA) and ROCK inhibitor Y-27632
(sc-3536) from Santa-Cruz Biotechnologies Inc. (Santa
Cruz, USA) were used in the study.
Cell lines and culture conditions
The human breast cancer cell line MDA-MB-231 was
routinely maintained in Dulbecco’s Modified Eagle
Medium (DMEM) (Sigma-Aldrich, Dorset, UK) supple-
mented with 10% fetal calf serum (FCS), penicillin and
streptomycin (Sigma-Aldrich, Dorset, UK). The cells
were incubated at 37°C, 5% CO2 and 95% humidity.
Human breast specimens
A total of 133 breast samples were obtained from breast
cancer patients (106 breast cancer tissues and 27 asso-
ciated background or related normal tissue), with the
consent of the patients and approved by the ethical com-
mittee. The pathologist verified normal background and
cancer specimens, and it was confirmed that the back-
ground samples were free from tumour deposit. These
tissues after mastectomy were immediately frozen in li-
quid nitrogen.
Over-expression of Claudin-5 in MDA-MB-231 breast
cancer cells
A range of normal human tissues were screened for
Claudin-5. Normal placenta tissue was chosen for en-
dogenous expression of Claudin-5. The human breast
cancer cell line MDA-MB-231was chosen forintroduction of the Claudin-5 gene. The gene, after ampli-
fication from placenta tissue cDNA was cloned into
aPEF6/V5-His TOPO TA plasmid vector (Invitrogen Ltd.,
Paisley, UK) breast cancer cells or MDA-MB-231. Expres-
sion of the gene was confirmed by RT-PCR. The Claudin-
5 expression construct and empty plasmid were, respect-
ively, used to transfect MDA-MB-231 cells by electropor-
ation. Stably transfected cells were then used for
subsequent assays after being tested at both transcriptional
and translational level. Those cells containing the expres-
sion plasmid and displaying enhanced Claudin-5 expres-
sion were designated MDA-MB-231CL5exp/MDACL5exp,
those containing the closed pEF6 empty plasmid and
used as control cells were designated MDA-MB-231pEF6/
MDApEF6 and unaltered wild type were designated MDA-
MB-231WT/MDAWT.
Generation of Claudin-5 ribozyme transgenes
Antihuman Claudin-5 hammerhead ribozymes were
designed based on the predictive secondary mRNA
structure using Zuker’s RNA mFold program as previ-
ously reported [23]. Those knockdown cells displaying
low levels of Claudin-5 were designated MDA-MB-
231CL5rib2/MDACL5rib2.
RNA extraction and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Cells were grown to confluence in a 25 cm3 flask before
RNA was extracted using total RNA isolation (TRI) re-
agent and following the protocol provided (Sigma-
Aldrich, Dorset, UK). RNA was converted to cDNA
using iScript cDNA synthesis kit (Primer Desing Ltd.,
Southampton, UK). Following cDNA synthesis, samples
were probed using actin primers to check the quality of
the cDNA and confirm uniform levels within each sam-
ple together with those specific for the Claudin-5 tran-
script (full primer sequences are outline in Table 1).
Conventional PCR was performed using a T-Cy Thermo-
cycler (Breacon Technologies Ltd., The Netherlands)
using REDTaqW ReadyMix™ PCR Reaction mix (Sigma-
Aldrich, Dorset, UK). Cycling conditions were as fol-
lowed: 94°C for 5 min, 94°C for 30 s, 55°C for 30 s, 72°C
for 30 s and the final extension phase at 72°C for 7 min
for 36 cycles. The PCR products were separated on a 2%
agarose gel and electrophoretically separated. The gel
was then stained with ethidium bromide prior to exam-
ine under ultraviolet light and photographs taken.
Real-time quantitative Polymerase Chain Reaction (Q-PCR)
The assay was based on the Amplifluor system. It was
used to detect and quantify transcript copy number of
Claudin-5 in tumour and background samples. Primers
were designed by Beacon Designer software, which
included complementary sequence to universal Z probe
Table 1 Primer sequences used in this study
Expression product Primer name Expression primer sequence (5′-3′) Predicted size (bp)
Claudin-5 CL5expR1 GACGTAGTTCTTCTTGTCGT 547
CL5expF2 ATGGGGTCCGCAGCGTTGGAGATCCT
CL5 ribozyme1 CL5ribF1 ACTAGTCCGCAGCGTTGGAGATTTCGTCCTCACGGACT 99
CL5ribR1 CTGCAGACAGCACCAGGCCCAGCTGATGAGTCCGTGAGGA
CL5 ribozyme2 CL5ribF2 CTGCAGCAGGTGGTCTGCGCCGTCACCTGATGAGTCCGTGAGGA 102
CL5ribR2 ACTAGTGACCGCCTTCCTGGACCACAACATTTCGTCCTCACGGACT
β-actin BACTF ACTGAACCTGACCGTACA 580
BACTR GGACCTGACTGACTACCTCA
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primer (which has the Z sequence), 10 pmol of FAM-
tagged universal Z probe (Intergen, Inc.) and cDNA
(equivalent to 50 ng RNA) (primer sequences are shown
in Table 1). Sample cDNA was amplified and quantified
over a large number of shorter cycles using an iCyclerIQ
thermal cycler and detection software (BioRad laborator-
ies, Hammelhempstead, UK) under the following condi-
tions: an initial 5 minute 94°C period followed by 60
cycles of 94°C for 10 seconds, 55°C for 15 seconds and
72°C for 20 seconds. Detection of GAPDH copy number
within these samples was later used to allow further
standardisation and normalisation of the samples.
SDS-PAGE, Western blotting and co-immunoprecipitation
MDA-MB-231 cells were grow to confluence, detached
and lysed in HCMF buffer containing 0.5% SDS, 0.5%
Triton X-100, 2 Mm CaCl2, 100 μg/ml phenylmethylsul-
fonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin
and 10 Mm sodium orthovanadate for 1 hour, sample
buffer was added and the protein boiled at 100°C for
5 min before being spun at 13,000 g for 10 min to re-
move insolubles. Protein concentration was quantified
using Bio-Rad Protein Assay kit (Bio-Rad Laboratories,
Hertfordshire, UK). Equal amounts of protein from each
cell sample were added onto a 10% or 15% (depending
on protein size) acrylamide gel and being subjected to
electrophoretic separation. The proteins were transferred
onto nitrocellulose membranes which were blocked and
probed with specific primary antibodies (1:500), follow-
ing with peroxidase-conjugated secondary antibody
(1:1000). Protein bands were visualized with Supersignal
West Dura system (Perbio Science UK Ltd., Cramling-
ton, UK) and detected using a CCD-UVIprochemin sys-
tem (UVItec Ltd., Cambridge, UK).
Co-immunoprecipitation samples were prepared as fol-
lows: cell lysate of the protein of interest was probed with
primary antibody (1:100 dilution) and placed on a rotating
wheel for 2 hour allowing Claudin-5 antibody to bind to
their targets. One hundred microlitres of conjugated A/G
protein agarose beads (Santa-Cruz Biotechnologies Inc.,USA) were added to each sample to make the antibody-
protein complex insoluble, followed by overnight incuba-
tion on the rotation wheel. The supernatant was discarded
and the pellet was washed in 200 μl of lysis buffer and
resuspended in 200 μl of 2X Lamelli sample buffer con-
centrate (Sigma-Aldrich, Dorset, UK), then denatured for
5 minutes by boiling at 100°C. Two Claudin-5 antibodies
were used to prevent cross-reactivity with N-WASP and
ROCK antibodies.
Trans-epithelial resistance (TER)
Cells were seeded into 0.4 μm transparent pore size
inserts (Greiner bio-one, Stonehouse, UK) at a density of
50,000 cells in 200 μl of ordinary medium within 24 well
plates, grown to confluence, the medium removed and
replaced with fresh Dulbecco’s Modified Eagle’s medium
containing 15 Mm Hepes, L-Glutamine ( Lonza Labora-
tories, Verviers, Belgium). Medium alone was added to
the base of the wells (control) or with 50 ng/ml HGF
[22]. Resistance across the layer of MDA-MB-231 cells
was measured using an EVON volt-ohmmeter (EVON,
World Precision Instruments, Aston, Herts, UK),
equipped with static electrodes (WPI, FL, USA) for a
period of 4 h.
In vitro cell growth assay
MDA-MB-231 cells were seeded into a 96 well plate at a
density of 3,000 cells/well to obtain density readings after
4 hours (day 0), 1 day, 3 days and 4 days. Within each
experiment four duplicates were set up. After appropri-
ate incubation periods, cells were fixed in 4% formalde-
hyde in BSS for 5-10 minutes before staining for 10
minutes with 0.5% (w/v) crystal violet in distilled water.
The crystal violet was then extracted from the cells using
10% acetic acid. Absorbance was determined at a wave-
length of 540 nm on a plate reading spectrophotometer.
In vitro cell matrix adhesion assay
The cell-matrix attachment was carried out as previously
described method [24]. Briefly, 45,000 cells were seeded
onto the Matrigel basement (10 μg/well) membrane in
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CO2 for 40 minutes. After the incubation period, the
medium was aspirated and the membrane washed 5 times
with 150 μl of BSS to remove the non-attached cells, then
fixed in 4% formaldehyde (v/v) in BSS for 10minutes be-
fore being stained in 0.5% crystal violet (w/v) in distilled
water. The number of adherent cells were counted from 5
random fields per well and 5 duplicate wells per sample,
under a microscope.
In vitro invasion cell assay
Cell culture inserts (BD FalcomTM Cell Culture Inserts,
BD Bioscience, Erembodegem, Belgium) were placed into
a 24-well plate using forceps and coated in Matrigel. The
working solution of Matrigel was prepared at a concentra-
tion of 0.5 mg/ml in PCR water, adding 100 μl to each in-
sert and allowing to dry overnight [25]. Once dried the
inserts were rehydrated in 100 μl sterile water for 1 hour.
The water was then aspirated and cells were seeded in the
inserts over the top of the artificial basement membrane
at a density of 30.000 cells in 200 μl per well. The plates
were then incubated for 3 days at 37°C with 5% CO2. After
the incubation period, the Matrigel layer together with the
non-invasive cells was cleaned from the inside of the in-
sert with a tissue paper. The cells which had migrated
through the Matrigel and porous membrane were fixed in
4% formaldehyde (v/v) in BSS for 10 minutes before being
stained in 0.5% crystal violet (w/v) in distilled water. The
cells were then visualized under the microscope under
X40 magnification, 5 random fields counted and duplicate
inserts were set up for each test sample.
In vitro Cytodex-2-bead motility assay
Cells were pre-coated onto Cytodex-2 beads (GE Health-
care, Cardiff, UK) for 2 hours [26]. The medium was aspi-
rated and the beads were washed 2X in growth medium to
remove non-adherent or dead cells. After the second wash
the beads were resuspended in 5 ml of normal growth
medium. Cell were aliquoted into a 24-well plate, 5 dupli-
cate wells per sample (300 μl/well), and incubated over-
night. Following incubation, any cells that had migrated
from the Cytodex-2 beads and adhered to the base of the
wells were washed gently in BSS, fixed in 4% formaldehyde
(v/v) in BSS for 10 minutes before being stained in 0.5%
crystal violet (w/v) in distilled water. Five random fields per
well were counted under microscope.
Wound healing assay
Forty thousand cells were seeded in a 24 well plate, and
upon reaching confluence, the medium was changed and
the monolayer was scraped with a fine gauge needle to
create a wound. The plate was placed on a heated plate
to keep a constant temperature of 37°C. Cells were
photographed after wounding and every 15 minutesduring 1 hour with a CCD camera attached to a micro-
scope at X20 magnification [27].
ECIS
The 1600R model of the ECIS (electric cell-substrate
impedence sensing) instrument (Applied Biophysics Inc,
NJ, USA) was used for motility assay (wounding assay),
wounding/cell modelling analysis in the study model.
The ECIS instrument measures the resistence/imped-
ance and capacitance of cells attached to a gold elec-
trode. Cell modelling was carried out using the ECIS
RbA modelling software, supplied by the manufacturer .
The 8 W10 arrays (8 well format with 10 probes in each
well) were used in the present study. The array surface
was treated with 200 μl of 10 mM L-Cysteine solution
for 20 minutes, which binds to the gold surface via its
thiol group forming a monomolecular layer, followed by
two washes in Dulbecco’s Modified Eagle’s medium with
15 Mm Hepes, L-Glutamine (Lonza Laboratories, Ver-
viers, Belgium). An electrode check was run to check
the impedance value of the cell-free wells containing just
fresh medium and to assess the integrity of the arrays.
The arrays were seeded at a density of 40,000 cells in
400 μl of Dulbecco’s Modified Eagle’s medium with
15 Mm Hepes, L-Glutamine to achieve confluent mono-
layers following treatment with motility-related inhibi-
tors. After 24 hours in culture, the confluence and
viability of the cell monolayer was confirmed by a light
microscope, thus another electrode check was run to
check the impedance value of the array to ensure correct
position of the contacts [27]. The monolayer of MDA-
MB-231 cells was electrically wounded with a 5 VAC at
4,000 Hz for 30 seconds. Impedance and resistance of
the cell layer were immediately recorded every millisec-
ond for a period of up to 5 hours.
Immunohistochemistry
Cryostat sections of frozen tissue were cut at 6 μm,
placed on Super Frost Plus slides (LSL UK, Rochdale,
UK), air dried and fixed in a 50:50 solution of alcohol:
acetone. The sections were then air dried again and
stored at -20°C until used. Immediately before com-
mencement of immuno-staining, the sections were
washed in buffer for 5 min and treated with horse serum
for 20 min as a blocking agent to non-specific binding.
Sections were stained using Claudin-5 antibodies (Santa-
Cruz Biotechnologies Inc., Santa Cruz, USA). Negative
controls were used where necessary. Primary antibodies
were used at 1:100 dilution for 60 min and then washed
in buffer. The secondary biotinylated antibody at 1:100
dilution (Universal secondary, Vectastain Elite ABC,
Vector Laboratories Inc., Burlingham, CA, USA) was
added (in horse serum/buffer solution) for 30 min, fol-
lowed by numerous washings. Avidin/Biotin complex
Escudero-Esparza et al. Journal of Experimental & Clinical Cancer Research 2012, 31:43 Page 6 of 18
http://www.jeccr.com/content/31/1/43was added for 30 min, again followed with washes.
Diaminobenzadine was used as a chromogen to visualize
the antibody/antigen complex. Sections were counter-
stained in Mayer’s haematoxylin for 1 min, dehydrated,
cleared and mounted in DPX.
In vivo development of mammary tumour
Athymic nude mice (nu/nu) were purchased from Charles
River Laboratories (Charles River Laboratories, Kent, UK)
and maintained in filter top units according to Home
office regulation. Each group of mice consisted of 5 mice
and each mouse was injected with a mix of 2x106 cancer
cells in 100 μl of sterile BSS containing 0.5 mg/ml Matrigel
suspension in both flanks. Two groups were included:
MDA-MB-231pEF6 control transfected cells, and MDA-
MB-231CL5exp displaying enhanced Claudin-5 expression.
The mice were weighted and the size of the growing
tumour measured using vernier callipers under sterile con-
ditions every week. Those mice that developed tumours
exceeding 1 cm3 or suffered 25% weight loss during the
experiment were terminated under Schedule 1 according
to the UK Home Office and the UK Coordinating Com-
mittee on Cancer Research (UKCCCR) instructions. At
the end of the experimental work, animals were weighed,
terminated under Schedule 1 and tumours were removed
if of sufficient size. Tumour volume was determined, at
each point, using the following formula: tumour volume =
0.523 x width2 x length.
Statistical analysis
Results data was analyzed using SigmaPlot software (ver-
sion 11.0). The statistical comparisons between the test
(MDA-MB-231CL5exp/MDACL5exp and MDA-MB-
231CL5rib2/MDACL5rib2) and the control cell line,
using as control wild type cells (MDA-MB-231WT/
MDAWT) or cells containing a closed pEF6/ V5-His
TOPO TA plasmid vector (MDA-MB-231pEF6/MDA
pEF6) were made using a Students two sample t-test and
by Two-way Anova test when the data was found to be
normalized and had equal variances. Comparisons be-
tween different patients groups were made using two
sample t-test where appropriate. In order to assess the
long term survival rates of patients with high and low
levels of Claudin-5, the overall survival data was used to
plot Kaplan-Meier survival curves (SPSS version 14).
Results
Claudin-5 expression was correlated with long-term survival
The expression of Claudin-5 was examined in breast
cancer specimens (tumour, n = 106; background, n = 27)
using real-time quantitative Polymerase Chain Reaction
(all values are displayed as mean Claudin-5 transcript
copies/μL of cDNA from 50 ng total RNA and normal-
ised by GAPDH). Initially long-term survival was analysedusing Kaplan-Meier survival curves (Figure 1a). Patients
were classified according to expression levels of CL-5,
guided by the Nottingham Prognostic Index (NPI) into
two groups; those with high levels and those with low
levels of Claudin-5. The cut off point was set at the level
at which patients were classified as moderate prognoses or
NPI 2Patients with high levels of Claudin-5 transcript had
a significantly shorter survival than patients with low
levels of Claudin-5 (p= 0.004); mean survival 129.780
moths (118.120-141.441 months, 95% CI) versus
66 months (41.520-90.480 months, 95% CI, cut-offs as
previously determined [24]). However, results revealed no
significant difference between tumour and normal/back-
ground samples (p= 0.38 (Figure 1b).
Correlation of Claudin-5 with prognosis, staging and
clinical outcome
To assess levels of expression of Claudin-5 with disease
progression, Claudin-5 transcript levels in the breast
cancer samples were analysed against The Nottingham
Prognostic Index (NPI), tumour-node-metastasis (TNM)
and histological grade. NPI, which indicates the pre-
dicted prognosis of the patients, was calculated using
the following equation [NPI = (0.2 X size) ± grade ± nodal
status], where NPI ≤ 3.4 is regarded as a good prognosis
(NPI 1), NPI 3.4-5.4 as moderate (NPI 2) and NPI ≥5.4
as poor prognosis (NPI 3). Claudin-5 levels were
increased in tumors with an NPI status of NPI3. There
were higher levels of Claudin-5 expression seen in
patients with poorer prognosis (Figure 1c), although
this did not reach significance (p = 0.34). The levels
of Claudin-5 were also analysed against tumour-node-
metastasis (TNM) (Figure 1d). There were higher levels
of Claudin-5 expression seen in TNM1 status when
compared to TNM2 (p = 0.19), TNM3 (p = 0.19) and
TNM4 (p = 0.19), but significance was not reached.
When comparing the levels of Claudin-5 against tumour
grade (Figure 1e), little difference in expression was
observed (p ≤ 0.85).
Patients who died of breast cancer had higher levels of
Claudin-5 transcript when compared with patients who
remained disease free although this did not reach signifi-
cance (p = 0.36) (Figure 1f ).
Distribution and expression of Claudin-5 in tumour and
background breast tissues
Claudin-5 immunohistochemical staining was observed
in the human breast tissue sections compared with its
staining in the normal mammary tissue (Figure 2). The
staining was used to assess the location, distribution and
the degree of staining of Claudin-5 in tumour and nor-
mal/background samples. In normal mammary tissues,
Claudin-5 appeared as strong staining in the endothelial
cells, lining vessels, whereas epithelial cells stained
Figure 1 Patients with breast cancer and high levels of Claudin-5 have reduced survival. (a) Patients with high levels of Claudin-5
transcript correlates with a significantly shorter survival (p = 0.004). (b) Claudin-5 mRNA level was increased in human breast tumors. (c) Claudin-5
transcript levels were increased in patients with poor prognosis (NPI 3). (d) Higher levels of Claudin-5 transcripts were seen in at TNM1. (e)
Claudin-5 transcript levels were decreased in grade 3 when compared to grade 1 and grade 2. (f) Patients who died of breast cancer had higher
levels of Claudin-5 transcript when compared with patients who remained disease free.
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Figure 2 Expression of Claudin-5 in mammary tissues
Immunohistochemical staining of Claudin-5 in normal/
background (left panel) tissue and tumour breast tissues (right
panel) is shown in consecutively increasing magnification.
Regions of Claudin-5 expression located at the TJ area in endothelial
and epithelial cells are indicated by arrows.
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the tumour sections was however, decreased in both
endothelial and epithelial cells. Moreover, the staining
distribution within cells from normal/background sec-
tions was concordant with TJ location. No such distribu-
tion was observed in cells from tumour sections. Here,
the staining was weak, diffuse and not located at the TJ.Generation of Claudin-5 knockdown and over-expression
in a human breast cancer cell line
A range of human tissues were screened for Claudin-5.
The Claudin-5 gene was successfully amplified from nor-
mal placenta tissue (Figure 3a). Following cloning and
transfection, the human breast cancer cell line MDA-MB-
231 was verified for Claudin-5 over-expression at both the
mRNA using RT-PCR and protein levels using Western
blot. The MDACL5exp cells demonstrated increased mRNA
and protein levels of Claudin-5 compared to MDAWT and
empty plasmid control MDApEF6 (Figure 3b).
In order to determine whether low levels of Claudin-5
has an effect on cells; ribozyme transgenes were generatedto down-regulate Claudin-5 expression in this cell line.
Two Claudin-5 targeting ribozyme, ribozyme 1 and ribo-
zyme 2, were transfected into the cells together with an
empty plasmid. Claudin-5 knockdown was verified at both
mRNA and protein levels using RT-PCR and Western blot-
ting (Figure 3c). However, ribozyme 1(MDACL5rib1) was un-
successful in knockdown of Claudin-5 expression; therefore
only the cells expressing low levels of Claudin-5 are further
referred to as MDACL5rib2. The MDACL5rib2 cells demon-
strated reduced mRNA and protein levels of Claudin-5
compared to the controls, MDAWT and MDApEF6. Immu-
nostaining revealed some increase in Claudin-5 at the cell
periphery (Figure 3d).
Claudin-5 did not alter cell growth in transfected human
breast cancer cells
The MDA-MB-231 sublines MDACl5exp and MDACL5rib2
alongside MDApEF6 were examined following 1, 3 and
4 day incubation periods using an in vitro cell growth
assay. No significant difference in the in vitro growth rate
of the MDApEF6 cells compared to MDACl5exp or MDACL5-
rib2 were found following the three different incubation
periods (Figure 4a).
Low levels of Claudin-5 reduces the cell adhesion to an
artificial Matrigel basement membrane
The ability of MDACl5exp and MDACL5rib2 cells to adhere
to matrix was assessed in an in vitro Matrigel adhesion
assay (Figure 4b). There was a significant difference be-
tween the adherence of MDACL5rib2 and MDApEF6 with
MDACL5rib2 cells being less adherent to matrix. In the
case of MDACl5exp, the opposite effect was seen, however
differences did not reach statistical significance when
compared to the control.
Claudin-5 did not alter the invasive phenotype of
transfected human breast cancer cells
The invasive potential of the transfected cells MDACl5exp
and MDACL5rib2 was examined using an in vitro Matrigel
invasion assay (Figure 4c). Both cell lines were found to
have no significant differences when compared to the
control MDApEF6 and invaded as individual cells, with
no apparent difference in invasion patterns.
Claudin-5 did not alter the in vivo tumour growth of
human breast cancer cells
The growth and capability of developing tumours of
MDA Cl5exp in an in vivo model was examined and com-
pared to the control MDApEF6 cells after subcutaneous in-
jection into the athymic nude mouse model. Over the
period of 33 days, no significant difference was observed
between the two groups, the control (injected with
MDApEF6) and those injected with MDACl5exp (Figure 4d).
Figure 3 Confirmation of over-expression and knockdown in MDA-MB-231 cells. (a) Screening of different human tissues for Claudin-5
coding sequence at mRNA level using RT-PCR. β-actin is used as a loading control. The placenta tissue was selected as a template. (b)
Verification of Claudin-5 over-expression and knockdown in MDA-MB-231cells. Claudin-5 levels were higher in MDA-MB-231 CL5exp
compared to the controls, as seen at mRNA level using RT-PCR. Claudin-5 expression was reduced in MDA-MB-231 CL5rib2 when
ribozyme 2 was used, at mRNA level using RT-PCR. (c) Protein level using Western blot analysis to show expression of Claudin-5. (d)
Immunofluorescence staining showing the distribution of Claudin-5 in Overexpressing cells (left) with Phalloidin to show actin (centre)
and merged (right).
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resistance (TER) in human breast cancer cells
Transepithelial resistance was measured to assess the
effect of over-expressing or knocking-down Claudin-5
on TJ functionality in MDA-MB-231 breast cancercells (Figure 4e). If the cells were to produce a higher
resistance, this is interpreted as them having increased
Tight Junction function; conversely, reduced resistance
implies a loss of cell-cell contact and a reduced Tight
Junction function. MDACl5exp showed increased TER
Figure 4 In vitro effect of Claudin-5 expression on and in vivo tumor development of MDA-MB-231 cells. (a) The cell growth of
MDACl5exp and MDACL5rib2 did not show any significant difference when compared to MDApEF6 (mean ± SD, n = 3). (b) The adhesive
capacity of MDACL5rib2 was significantly decreased in comparison with the control MDApEF6 (p≤ 0.001) (mean ± SD, n = 3). (c) The
invasive capacity of MDACl5exp and MDACL5rib2 did not show any significant difference when compared to MDApef6 (mean ± SD, n = 3).
(d) There were no significant differences in tumor growth over 33 day period (p = 0.29). (e) A significant increase was seen in TER of
MDACL5rib2 over a period of 4 hours when compared to the control (p≤ 0.001) (mean±SD, n = 3). (f) Effect of Claudin-5 on
transepithelial resistance on MDA-MB-231 cells after treatment with HGF showed significant decreases in TER in control cells MDApEF6
over a period of 4 hours when compared to the untreated cells (using ANOVA p≤ 0.05 versus respective untreated cells) (mean±SD,
n = 3). (g) Significant decreases in TER were also seen in the transfected cells MDA CL5exp after treatment with HGF (using ANOVA
p≤ 0.05 versus respective untreated cells) (mean±SD, n = 3) and in MDA CL5rib2 (h) (using ANOVA p≤ 0.05versus respective untreated
cells) (mean±SD, n = 3).
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MDApEF6. Changes in TER were more evident in
MDACL5rib2 when compared to the control. Treatment of
cells with HGF (50 ng/ml) resulted in a significant reduc-
tion of the transepithelial resistance in transfected and in
control cells when compare to untreated cells over a
period of 4 hours (Figure 4f, g, h).Low levels of Claudin-5 retarded the motility and
migration of human breast cancer cells
Transfected and control cells, either untreated or treated
with HGF, were evaluated for their motility using a Cyto-
dex-2 bead motility assay to explore the possibility of
Claudin-5 involvement in motility. The aim of this assay
is to evaluate the number of motile cells that are able to
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vessel floor. MDA Cl5exp cells did not show significant dif-
ferences when compared to the control. In contrast,
MDACL5rib2 cells demonstrated a significant reduction in
cell motility compared to the control (Figure 5a). The
cells were additionally evaluated after treatment with
HGF. This motogen increased cell motility in MDACl5exp
and control cells when compared to untreated. In the
case of MDACL5rib2, changes in motility were not found
to be significant (Figure 5b).
The effect of Claudin-5 on cell migration was assessed
using an in vitro cellular migration/wound healing assay.
MDACl5exp showed a significant increase in cellular mi-
gration compared to the control 60 minutes after. A sig-
nificant decreased cell migration was seen in
MDACL5rib2 after 60 minutes when compared to control
(Figure 5c). In this assay, we are investigating the direct
movement of cells as they migrate from a cell layer into
open space. The cytodex-2 bead assay in comparison,
measures the motility of single cells. It is not surprising
that the over-expression or knock-down of Claudin-5
appears to be more significant in the wounding assay; it
appears that Claudin-5 might be involved in the signal-
ling pathway for changes in contact inhibition and
changes in the cytoskeleton, rather than in simple motil-
ity (as assessed using the bead assay).
Using ECIS (Electrical Cell Impedance Sensing) and in
recovering from electrical wounding (5 VAC for 30 sec-
onds), it was shown that the MDACl5exp cells were sig-
nificantly more motile compared to the control cells as
the resistance in the electrode increased as the cells
begin to spread over the electrode, whereas the opposite
trend was seen in MDACL5rib2, where a significant reduc-
tion in migration was seen (Figure 5d).
Claudin-5 and control of cell motility involving the N-WASP
and ROCK signalling pathways
To address the possibility that Claudin-5 might play a role
in regulating cell motility, different motility-regulators were
studied in order to search for any possible links between
Claudin-5 and a range of motility-related proteins. Cell mo-
tility was analysed using ECIS after being treated with dif-
ferent motility inhibitors and the motogen HGF. Following
electrical wounding (5 VAC for 30 seconds) and treatment
with HGF (50 ng/ml), MDApEF6 ±HGF, MDACl5exp ±HGF
and MDACL5rib2 ±HGF showed an increase in motility
when compared to untreated cells. It was significantly
enhanced after 5 hours of treatment (Figure 6a). Following
experiments then examined the effect of motility inhibitors
alone. When cells were treated with the N-WASP inhibitor
(50 μM), the migration rate of MDApEF6 ±N-WASP, MDA-
Cl5exp ±N-WASP and MDACL5rib2 ±N-WASP was mark-
edly reduced after 5 hours of treatment when compared to
untreated cells (Figure 6b). The ROCK inhibitor (50nM) wascapable of altering the motility of MDApEF6 ±ROCK when
compared to the untreated cells. However, no significant
differences were found in the transfected cells, MDACl5exp ±
ROCK and MDACl5rib2 ±ROCK, when compared to the
untreated cells (Figure 6c). All these results were based on 3
repeat experiments that were combined and analysed using
ANOVA.
In order to investigate any possible effect of Claudin-5
on protein level of N-WASP and ROCK 1, Western blot
analysis was used to assess whether any direct effect was
exerted at the protein level in the control and transfected
cells. MDA-MB-231Cl5exp and MDA-MB-231CL5rib2
Western blotting demonstrated very low levels of the N-
WASP at protein level which was undetectable in MDA-
MB-231pEF6 (Figure 7a). Protein levels of ROCK 1
showed a similar low level in all cells (Figure 7a). Thus,
modulation of Claudin-5 appeared to cause an increase
in N-WASP expression at the protein level.
Immunoprecipitation of Claudin-5 followed by immuno-
blotting with N-WASP and ROCK 1 was used in order to
investigate a possible interaction between Claudin-5 and
N-WASP as well as with ROCK 1. Results showed a pro-
tein-protein interaction between Claudin-5 and these mo-
tility-related proteins in MDA-MB-231pEF6 and MDA-
MB-231Cl5exp (Figure 7b, negative controls shown below).
In keeping with this, immunoprecipitation with either N-
WASP (Figure 7c) or ROCK1 (Figure 7d) followed by im-
munoblotting with Claudin-5 produced consistent results.
Discussion
In this present study, we used cells transfected with
Claudin-5 expression sequence and ribozyme transgenes to
assess the impact of reducing the expression of our protein
of interest as well as enhancing it in order to evaluate
changes in the aggressive nature of MDA-MB-231 breast
cancer cells. We also demonstrated for the first time that
there is a link between Claudin-5 and cell motility. The dis-
ruption of the Tight Junction (TJ) structure is a common
feature of many human cancer cells. Downregulation of dif-
ferent TJ proteins has been linked with staging and meta-
static potential in various cancers including breast [28].
Indeed, in human breast cancer, tumour tissues show trun-
cated and/or variant signals for occludin. Knockdown of
occludin resulted in increased invasion, reduced adhesion
and significantly reduced TJ functions, whilst Q-RT-PCR
showed occludin to be significantly decreased in patients
with metastatic disease [29]. This loss of or aberrant expres-
sion has clear repercussions as to the importance of occlu-
din in maintaining TJ integrity in breast tissues and could
play a part in breast cancer development. In addition,
in vivo and in vitro data has revealed that over-expression
of TJ proteins in cancer cells, such as Claudin-4, leads to a
decrease in invasiveness and metastases in animal models
[29]. Similar conclusions were found when cells breast
Figure 5 Effect of Claudin-5 on cell motility of MDA-MB-231 cells. (a) Cytodex-2 bead motility assay was used. The motility of MDA CL5rib2
was significantly reduced in comparison to the control MDA pEF6 (using one-tailed test, p = 0.027) (mean±SD, n = 3). (b) Effect on cell motility after
treatment with HGF using a Cytodex-2 bead motility assay. Transfected and control cells showed an increase in motility, however only MDA Cl5exp
results were significant (p≤ 0.001 versus respective untreated cells) (mean±SD, n = 3). (c) Effect of Claudin-5 on cell migration was assessed by a
migration/wound healing assay. MDACL5expcells showed an increase in migration when compared to the control at 60 minutes after wounding
(*p≤ 0.005) (mean± SD, n = 3). The migration of MDACl5rib2 was reduced in comparison to the control at 60 minutes (**p≤ 0.005) (mean± SD,
n = 3). (d) Significant differences using ECIS were revealed after wounding. MDACL5exp showed significant increased migration (p≤ 0.001) whereas
MDACl5rib2 showed a decreased migration rate (p≤ 0.001) (n = 3).
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in invasiveness and motility [26]. Since claudin-18 is over-
expressed in precursor lesion PanIN and pancreatic ductcarcinoma, it serves as a diagnostic marker and a target of
immunotherapy [30]. The upregulation of claudin-18 by
TPA in human pancreatic cancer cell lines can be
Figure 6 Effect of Claudin-5 on MDA-MB-231 cell migration following treatment with HGF, N-WASP inhibitor or ROCK inhibitor using
ECIS. (a) Migration was significantly increased in MDApEF6 ±HGF, MDACl5exp ±HGF and MDACL5rib2 ± HGF when compared to untreated cells
(p≤ 0.001, p≤ 0.001 and p= 0.003 versus respective untreated controls) (n = 3). (b) Migration was significantly decreased in MDApEF6 ±N-WASP
inhibitor, MDACl5exp ±N-WASP inhibitor and MDACL5rib2 ± N-WASP inhibitor when compared to untreated cells (p≤ 0.001, p = 0.006 and p= 0.018
respectively) (n = 3). (c) Migration was significantly decreased in MDApEF6 ± ROCK inhibitor (p≤ 0.001). MDACl5exp ± ROCK inhibitor and
MDACL5rib2 ± ROCK inhibitor did not show significant differences when compared to untreated cells (p = 0.403 and p= 0.072 respectively) (n = 3).
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the upregulation of claudin-18 by TPA in hTERT-HPDE
cells is prevented by inhibitors of PKCδ, PKCθ, and PKCα.
This suggests that in human pancreatic cancer cells clau-
din-18 is primarily regulated at the transcriptional level via
specific PKC signaling pathways and modified by DNA
methylation [30]. These studies have provided promising
evidence that TJ proteins might serve as useful molecular
targets in the prognosis of cancer. In prostate, claudin-4
was down-regulated and claudins-2, -3, and -5 were overex-
pressed in prostate adenocarcinomas compared with be-
nign prostatic hyperplasia samples. Expression of claudins-
1 and-7 was similar in tumours and benign prostatic hyper-
plasia samples. Claudin-11 was absent from all prostate
samples. Overexpression of claudin 3 was associated with
perineural invasion and tended to occur in advanced stages
of the disease. Increased expression of Claudin-5 was mar-
ginally associated with perineural invasion. Such results
suggest that alterations in claudin expression occur inprostate cancer cells, although there was no association
with clinicopathological parameters [31].
Initially, the role of Claudin-5 was investigated when
transepithelial electric resistance (TER) was measured.
Transepithelial electric resistance (TER) is the easiest
and most sensitive measure of barrier strength.
MDACL5rib2 showed the highest resistance, whereas the
resistance of MDACl5exp and the control were lower and
followed the same trend, although MDACl5exp was sig-
nificantly higher than control cells. These preliminary
results revealed that Claudin-5 was not playing a real
role in keeping the cell barrier tight. In fact, the com-
pensation of the lack of Claudin-5 could be balanced
with one of the other 23 members of the Claudin family
which might alter the barrier strength, therefore explain-
ing why the knockdown cells displayed higher transe-
pithelial resistance. The same explanation could be
applied to forced-expression and the very similar trends
that it shared with the control cells.
Figure 7 Western blot demonstrating levels of expression of N-WASP and ROCK 1 and protein-protein interactions. (a) Expression of
N-WASP and ROCK 1 in transfected and control cells. (b) Co-immunoprecipitation of Claudin-5 with N-WASP and ROCK 1. (c) Co-
immunoprecipitation of N-WASP with Claudin-5. (d) Co-immunoprecipitation of ROCK 1 with Claudin-5.
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although there appeared not to be an involvement of
Claudin-5 in cell growth. Cell adhesion to extracellular
matrix is fundamental in the organization of the epithe-
lium as a continuous layer but also in the regulation ofmany cellular processes such as motility [32]. MDACL5rib2
demonstrated a decrease in adhesion whereas MDACl5exp
appeared to increase adhesion when compared to the con-
trol cells, although these results did not reach significance.
Integrins enable cancer cells to identify their surrounding
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maintenance of positional stability in normal epithelia; in
breast cancer however, it has been suggested that there
may be a link between integrins and metastasis [33]. The
question therefore arises as to whether the absence of
Claudin-5 in a cell alters levels of integrins and other ad-
hesion-related proteins, thus changing the adhesion of the
cancer cell when compared to the control. The invasive-
ness of the cells through the ECM did not show any
relevant differences between cells over-expressing or
knocking-down levels of Claudin-5. This result agrees
with the data obtained in the in vivo experiments,
where the MDACl5exp cells were analysed for their abil-
ity to grow and develop in nude mice. Over a period
of one month, no differences were found between the
two groups of animals, the control (injected with
MDApef6) and those injected with MDACl5exp. Taking
these results together, we began to speculate whether
Claudin-5 might be involved in cell motility. We per-
formed a further set of experiments to assess the level
of involvement of Claudin-5 in breast cancer motility.
As breast cancer cells acquire a motile phenotype, this
is translated into changes in highly dynamic structures
like actin filaments and cytoplasmic microtubular com-
plex [34]. We decided to investigate the effects on mo-
tility of over-expression or knockdown of Claudin-5.
To achieve this, an in vitro motility assay and a trad-
itional wound healing assay was carried out, both re-
vealing that MDACL5rib2 showed a reduction in
motility. Moreover, ECIS was used in order to measure
in real time how fast cells migrate after wounding.
Similar results were obtained; MDACL5rib2 was indeed
slower when compared to the control. However, MDA-
Cl5exp cells were the fastest in each of the assays men-
tioned above. Until now, we have shown that
knockdown of Claudin-5 expression in a breast cancer
cell line resulted in a less adhesive and less motile cell
phenotype when compared to controls. The opposite
was seen when Claudin-5 expression was forced,
resulting in a more adhesive and more motile pheno-
type but with no differences in invasiveness in vivo
and in vitro. We might tentatively conclude from this
that Claudin-5 might be a motility regulator, or at
least have a role in the motility of these human breast
cancer cells.
Previously, we have carried out a significant body of
work on the role and effect of HGF in epithelial cancer
cells. HGF is a powerful motogen able to promote prolif-
eration, invasion, and migration of epithelial cells by
binding to its tyrosine kinase receptor c-met [35] as well
as modulating expression and function of TJ molecules
in human breast cancer cell lines and decreasing trans-
epithelial resistance [21]. Cells displaying enhanced or
suppressed expression of Claudin-5 respond in keepingwith the well established effect after treatment with HGF,
showing reduced epithelial resistance and increased mo-
tility. ECIS experiments corroborated these results. It is
interesting that claudin-7 expressing human lung cancer
cells have been shown to have a reduced response to
HGF, are less motile, and form fewer foot processes
than untreated cells. In addition, cells transfected with
claudin-7 dramatically decreased their invasive ability
after HGF treatment. It has been shown that this is
mediated through the MAPK signalling pathway since
the phosphorylation level of ERK1/2 was significantly
lower in claudin-7 transfected cells than in control
cells [36].
To address the possibility that Claudin-5 might play a role
in regulating cell motility, different motility-regulators were
studied in order to search for any possible links between
Claudin-5 and a range of motility-related proteins. Cell mo-
tility was analysed using ECIS after being treated with differ-
ent motility inhibitors. In particular the N-WASP inhibitor
(Wiskostatin) and the ROCK inhibitor (Y-27632) responded
in an unexpected way in our transfected cells. Neuronal
Wiskott - Aldrich syndrome protein, N-WASP, is ubiqui-
tously expressed in mammalian tissues and it is responsible
for connecting several signalling pathways to the initiation
of actin assembly via the Arp2/3 complex. N-WASP has
been reported to exist in a self-folded auto-inhibited con-
formation. When activated, conformational changes occur
facilitating the interaction with the Arp2/3 complex and
subsequent nucleation [37]. The Rho-associated serine-
threonine protein kinase, ROCK, is ubiquitously expressed
in mammalian tissues and it is directly linked, after activa-
tion, with numerous processes related to actin-myosin, such
as actin cytoskeletal reorganisation and the formation of
focal adhesions. It also has an important role in cell migra-
tion by promoting the contraction of the cell body and is
required for tail retraction in cancer cells [38]. The trans-
fected and control cells were treated with the N-WASP in-
hibitor, responsible for stabilising the auto-inhibited
conformation of the N-WASP protein [39], and their rate
of speed was measured using ECIS after wounding. Results
showed an inhibition in their motility, however, this inhib-
ition was marginally reduced in knockdown cells. The effect
of the ROCK inhibitor (Y-27632) was also studied in our
cells. The inhibitor specificity is, however, questioned as
in vitro studies revealed that it not only exerts an inhibitory
effect on ROCK proteins but also on other kinases [40].
Nevertheless, the control cells responded to its inhibition
showing a lower rate of migration; conversely both trans-
fected cells did not respond to its inhibitory effects. Thus
far we have shown that the absence of Claudin-5 clearly
caused an alteration in cell motility as the ROCK inhibitors
were no longer inhibiting cell motility in MDACL5rib2.
Additionally, in the case of MDACL5rib2 cells treated with
N-WASP inhibitor, we observed some inhibition, but at a
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hibitor in control and MDACl5exp cells.
The next question to be addressed following the
ECIS results, was to investigate any possible protein-
protein interaction between Claudin-5 and N-WASP
or Claudin-5 and ROCK 1 as well as whether any dir-
ect effect was occurring at the protein level of these
molecules in the control and transfected cells. Co-
immunoprecipitation with Claudin-5, followed by im-
munoblotting with either N-WASP or ROCK 1
demonstrated an interaction between Claudin-5 and
N-WASP as well as with ROCK 1. To confirm these
interactions, a co-immunoprecipitation with either
N-WASP or ROCK 1 followed by immunoblotting
with Claudin-5 was carried out confirming the inter-
actions between these protein pairs. Previously, stud-
ies have already linked TJ with N-WASP. The
intestinal epithelial cells, T84, when treated with
N-WASP inhibitor showed an inhibition in the for-
mation of TJ [41]. A more recent study using Sertoli
cells linked the inhibition of N-WASP, and therefore
the inhibition of Arp2/3, in the nucleation process
with barrier disruption in the blood-testis barrier
causing a failure of spermatic transit [40]. N-WASP
protein in MDA-MB-231 human breast cancer cells
has been reported to be expressed at a very low level
[25]. The results obtained in the current study agree.
The levels of ROCK 1 did not show any real differ-
ences among transfected and control cells, this pos-
sibly could be due to the high level of this protein
found in MDA-MB-231 wild type cells as already
reported [38].
This work suggests that Claudin-5 might be involved in
cancer cell motility; in particular, it appears to be involved
in the signalling pathway of N-WASP and ROCK. How-
ever, understanding cell motility requires detailed know-
ledge not only of the signalling networks, but also about
their dynamics. This possible new role of Claudin-5 in
breast cancer cell motility opens the door to future studies
in which Claudin-5 and therefore TJ might switch from
static structures to very dynamic ones, and offers an excit-
ing glimpse into how modulation of transmembrane TJ
proteins could be targeted in cancer metastasis.
Previous studies have revealed the differential expres-
sion of Claudins in human cancers [32]. Although high
levels of Claudin-5 have been reported in ovarian [6],
prostate [42] and lung cancers [5] and low levels in hepa-
tocellular carcinoma [43], this is the first study to our
knowledge to report levels of Claudin-5 in patients with
breast cancer. We have shown for the first time that
Claudin-5 is aberrantly expressed in human breast can-
cer and has a link to the clinical outcome of the patient.
From this data we have observed that Claudin-5 expres-
sion is increased in breast tumour tissue compared tonormal/background endothelial cells, however this result
did not correlate with IHC staining, where levels of
Claudin-5 protein appear to be higher in normal/back-
ground tissues when compared to tumour sections. This
discrepancy may be due to the non-discriminatory na-
ture of Q-PCR, as we have not been able to specifically
compare the levels of Claudin-5 in endothelial cells
from normal mammary tissues and breast cancer tis-
sues. In early studies Claudin-5 was described as a pro-
tein highly expressed in endothelial cells of the blood
vessels [16] this might also help us to explain the dispar-
ity founded between the IHC and Q-PCR results. More-
over, IHC is a semi-quantitative method. For the clinical
point of view, one of the most interesting observations
from this study is the relationship between high levels
of Claudin-5 and clinical outcome. Patients who died
from breast cancer had higher levels of Claudin-5 com-
pared with patients who remained disease-free. Further-
more, patients whose tumours expressed high levels of
Claudin-5 had significantly shorter survival than those
with low levels of expression of Claudin-5.
There is now a body of work highlighting the potential
roles of claudins in human breast cancer, where low levels
of some claudins (-3, -4 and -5), termed claudin-low rep-
resent a subtype of breast cancer in patients with poor
prognosis and features of mesenchymal and mammary
stem cells [44]. It appears that Claudin-5 has a different
role in breast cancer, functioning as a potential motility
regulator. Although this does not prevent other claudins
having a role in Tight Junction function itself, it appears
that Claudin-5 has a more unique function. Future work
would hope to unravel it’s function as distinct from other
claudins’. Collectively, these findings suggest that Claudin-
5 is a potential prognostic factor in patients with breast
cancer, as high levels of expression are clearly associated
with indicators of poor prognosis as well as with high inci-
dence of breast cancer-related death and shorter survival
of patients. This report indicates that Claudin-5 has a po-
tential as a prognostic indicator in human breast cancer .
Conclusions
From the data presented here, we can reveal a link be-
tween Claudin-5 and cell motility in breast cancer cells.
Furthermore, Claudin-5 has potential as a prognostic
tool in human breast cancer, in particular with relevance
to patient survival and outcome. Many questions still
need to be answered and whilst high motility phenotypes
might not lead to malignant progression per se, the con-
trol of motility by Claudin-5 could be a contributing fac-
tor to metastatic disease in human breast cancer.
Abbreviations
N-WASP: Neuronal wiskott aldrich syndrome protein; ROCK: Rho kinase;
TJ: Tight Junction; ECM: Extracellular matrix; EMT: Epithelial-mesenchymal
transition; TMVCF: Transmembrane protein deleted in velo-cardio-facial
Escudero-Esparza et al. Journal of Experimental & Clinical Cancer Research 2012, 31:43 Page 17 of 18
http://www.jeccr.com/content/31/1/43syndrome; BBB: Blood brain barrier; HGF: Hepatocyte growth factor;
Q-PCR: Quantitative polymerase chain reaction; HCMF: Hepes buffer, calcium
and magnesium free; ECIS: Electric cell-substrate impedance sensing;
RT-PCR: Reverse transcriptase-polymerase chain reaction; NPI: Nottingham
prognostic indicator.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AEE carried out the molecular and cell biology work and drafted the
manuscript. WGJ conceived of the initial plan, designed primers and carried
out Q-PCR and sourced the patient samples. TAM completed the
manuscript, planned the experiments and provided additional laboratory
help, carried out Q-PCR and contributed to the overall design of the work.
All authors read and approved the final manuscript.
Acknowledgement
We would like to thank Cancer Research Wales for supporting this work.
Received: 25 January 2012 Accepted: 18 February 2012
Published: 4 May 2012
References
1. Crnic I, Christofori G: Novel technologies and recent advances in
metastasis research. Int J Dev Biol 2002, 48(5–6):573–581.
2. Yang J, Mani SA, Weinberg RA: Exploring a new twist on tumor
metastasis. Cancer Res 2006, 66(9):4549–4552.
3. Nishimura Y, Itoh K, Yoshioka K, Tokuda K, Himeno M: Overexpression of
ROCK in human breast cancer cells: evidence that ROCK activity
mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res
2002, 9(2):83–95.
4. Martin TA, Das T, Mansel RE, Jiang WG: Synergistic regulation of
endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid
(GLA) via Claudin-5 modulation. J Cell Biochem 2002, 98(5):1308–1319.
5. Paschoud S, Bongiovanni M, Pache JC, Citi S: Claudin-1 and Claudin-5
expression patterns differentiate lung squamous cell carcinomas from
adenocarcinomas. Mod Pathol 2002, 20(9):947–954.
6. Turunen M, Talvensaari-Mattila A, Soini Y, Santala MZ: Claudin-5
overexpression correlates with aggressive behavior in serous ovarian
adenocarcinoma. Anticancer Res 2002, 29(12):5185–5189.
7. Arshad F, Wang L, Sy C, Avraham S, Avraham HK: Blood-brain barrier
integrity and breast cancer metastasis to the brain. Patholog Res Int 2010,
2011:920509.
8. Martin TA, Mason MD, Jiang WG: Tight junctions in cancer metastasis.
Front Biosci 2011, 16:898–936.
9. Cereijido M, Contreras RG, Shoshani L, Flores-Benitez D, Larre I: Tight
junction and polarity interaction in the transporting epithelial
phenotype. Biochim Biophys Acta 2008, 1778(3):770–793.
10. Tsukita S, Furuse M: Pores in the wall: claudins constitute tight junction
strands containing aqueous pores. J Cell Biol 2000, 149(1):13–16.
11. Ohkubo T, Ozawa M: J The transcription factor Snail downregulates the
tight junction components independently of E-cadherin downregulation.
Cell Sci 2002, 117(Pt 9):1675–1685.
12. Morita K, Furuse M, Fujimoto K, Tsukita S: Claudin multigene family
encoding four-transmembrane domain protein components of tight
junction strands. Proc Natl Acad Sci U S A 1999, 96(2):511–516.
13. Furuse M, Sasaki H, Tsukita S: Manner of interaction of heterogeneous
claudin species within and between tight junction strands. J Cell Biol
1999, 147(4):891–903.
14. Tsukita S: Isolation of cell-to-cell adherens junctions from rat liver. J Cell
Biol 1989, 108(1):31–41.
15. Van Itallie CM, Anderson JM: Claudins and epithelial paracellular transport.
Annu Rev Physiol 2006, 68:403–429.
16. Morita K, Sasaki H, Furuse M, Tsukita S: Endothelial claudin: Claudin-5/
TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol
1999, 147(1):185–194.
17. Rahner C, Mitic LL, Anderson JM: Heterogeneity in expression and
subcellular localization of claudins 2, 3, 4, and 5 in the rat liver,
pancreas, and gut. Gastroenterology 2009, 120(2):411–422.18. Amasheh S, Schmidt T, Mahn M, et al: Contribution of Claudin-5 to barrier
properties in tight junctions of epithelial cells. Cell Tissue Res 2005,
321(1):89–96.
19. Wolburg H, Wolburg-Buchholz K, Kraus J, et al: Localization of claudin-3 in
tight junctions of the blood-brain barrier is selectively lost during
experimental autoimmune encephalomyelitis and human glioblastoma
multiforme. Acta Neuropathol 2003, 105(6):586–592.
20. Nitta T, Hata M, Gotoh S, et al: Size-selective loosening of the blood-brain
barrier in Claudin-5-deficient mice. J Cell Biol 2003, 161(3):653–660.
21. Martin TA, Watkins G, Mansel RE, Jiang WG: Hepatocyte growth factor disrupts
tight junctions in human breast cancer cells. Cell Biol Int 2004, 28(5):361–371.
22. Martin TA, Watkins G, Mansel RE, Jiang WG: Loss of tight junction plaque
molecules in breast cancer tissues is associated with a poor prognosis in
patients with breast cancer. Eur J Cancer 2004, 40(18):2717–2725.
23. Jiang WG, Davies G, Martin TA, et al: Targeting matrilysin and its impact
on tumor growth in vivo: the potential implications in breast cancer
therapy. Clin Cancer Res 2003, 11(16):6012–6019.
24. Jiang WG, Hiscox SE, Parr C, et al: Antagonistic effect of NK4, a novel
hepatocyte growth factor variant, on in vitro angiogenesis of human
vascular endothelial cells. Clin Cancer Res 1999, 5(11):3695–3703.
25. Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG: N-WASP is a putative
tumour suppressor in breast cancer cells, in vitro and in vivo, and is
associated with clinical outcome in patients with breast cancer. Clin Exp
Metastasis 2008, 25(2):97–108.
26. Martin TA, Harrison GM, Watkins G, Jiang WG: Claudin-16 reduces the aggressive
behavior of human breast cancer cells. J Cell Biochem 2008, 105(1):41–52.
27. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF, Puntis MC: Inhibition of
hepatocyte growth factor-induced motility and in vitro invasion of human
colon cancer cells by gamma-linolenic acid. Br J Cancer 1995, 71(4):744–752.
28. Hoover KB, Liao SY, Bryant PJ: Loss of the tight junction MAGUK ZO-1 in
breast cancer: relationship to glandular differentiation and loss of
heterozygosity. Am J Pathol 1999, 153(6):1767–1773.
29. Martin TA, Mansel RE, Jiang WG: Loss of occludin leads to the progression
of human breast cancer. Int J Mol Med 2010, 26(5):723–734.
30. Ito T, Kojima T, Yamaguchi H, Kyuno D, Kimura Y, Imamura M, Takasawa A,
Murata M, Tanaka S, Hirata K, Sawada N: Transcriptional regulation of
claudin-18 via specific protein kinase C signaling pathways and
modification of DNA methylation in human pancreatic cancer cells. J Cell
Biochem 2011, 7:1761–1772.
31. Coutinho-Camillo CM, Lourenço SV, da Fonseca FP, Soares FA: Claudin expression
is dysregulated in prostate adenocarcinomas but does not correlate with main
clinicopathological parameters. Pathology 2011, 43(2):143–148.
32. Michl P, Barth C, Buchholz M, et al: Claudin-4 expression decreases
invasiveness and metastatic potential of pancreatic cancer. Cancer Res
2003, 63(19):6265–6271.
33. Felding-Habermann B, O’Toole TE, Smith JW, et al: Integrin activation
controls metastasis in human breast cancer. Proc Natl Acad Sci U S A
2009, 98(4):1853–1858.
34. Insall RH, Jones GE: Moving matters: signals and mechanisms in directed
cell migration. Nat Cell Biol 2006, B(8):776–779.
35. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T:
Hepatocyte growth factor, its receptor, and their potential value in
cancer therapies. Crit Rev Oncol Hematol 2005, 53(1):35–69.
36. Lu Z, Ding L, Hong H, Hoggard J, Lu Q, Chen YH: Claudin-7 inhibits human
lung cancer cell migration and invasion through ERK/MAPK signalling
pathway. Exp Cell Res 2011, 1;317(13):1935–1946.
37. Dovas A, Cox D: Regulation of WASp by phosphorylation: Activation or
other functions? Commun Integr Biol 2010, 3(2):101–105.
38. Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG: The expression and
prognostic value of ROCK I and ROCK II and their role in human breast
cancer. Int J Oncol 2008, 33(3):585–593.
39. Guerriero CJ, Weisz OA: N-WASP inhibitor wiskostatin nonselectively
perturbs membrane transport by decreasing cellular ATP levels. Am J
Physiol Cell Physiol 2007, 292(4):C1562–C1566.
40. Grise F, Bidaud A, Moreau V: Rho GTPases in hepatocellular carcinoma.
Biochim Biophys Acta 2009, 1795(2):137–151.
41. Ivanov AI, Hunt D, Utech M, Nusrat A, Parkos CA: Differential roles for actin
polymerization and a myosin II motor in assembly of the epithelial
apical junctional complex. Mol Biol Cell 2005, 16(6):2636–2650.
42. Seo KW, Kwon YK, Kim BH, et al: Correlation between Claudins Expression
and Prognostic Factors in Prostate Cancer. Korean J Urol 2010, 51(4):239–244.
Escudero-Esparza et al. Journal of Experimental & Clinical Cancer Research 2012, 31:43 Page 18 of 18
http://www.jeccr.com/content/31/1/4343. Sakaguchi T, Suzuki S, Higashi H, et al: Expression of tight junction protein
Claudin-5 in tumor vessels and sinusoidal endothelium in patients with
hepatocellular carcinoma. J Surg Res 2008, 47(1):123–131.
44. Prat A, Parker JS, Karingova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou
CM: Phenotypic and molecular characterization of the claudin-low
intrinsic subtype of breast cancer. Breast Can Res 2010, 12:R68.
doi:10.1186/1756-9966-31-43
Cite this article as: Escudero-Esparza et al.: Claudin-5 is involved in
breast cancer cell motility through the N-WASP and ROCK
signalling pathways. Journal of Experimental & Clinical Cancer Research
2012 31:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
